Precision medicine: Sustained response to erdafitinib in FGFR2-mutant, multiply recurrent ameloblastoma

BACKGROUNDAmeloblastoma imposes significant morbidity and high-recurrence rates following surgery and radiation therapy. Although 89% of cases harbor oncogenic mutations, the role of targeted therapy is undefined. CASEWe describe a case of a 40-year-old male with multiply recurrent, locally invasive...

Full description

Bibliographic Details

Published in:	Cancer reports (Hoboken, N.J.) Vol. 5; no. 10; p. e1656
Main Authors:	Lawson-Michod, Katherine A, Le, Christopher H, Tranesh, Ghassan, Thomas, Penelope C, Bauman, Julie E
Format:	Report
Language:	English
Published:	01-10-2022
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!